Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829489 | 0.94 | FBP1 (1.00) | FBP1 | |
| SCHEMBL6827044 | 0.93 | FBP1 (0.86) | FBP1 | |
| SCHEMBL6829670 | 0.90 | FBP1 (1.00) | FBP1 | |
| SCHEMBL4956202 | 0.90 | FBP1 (1.00) | FBP1 | |
| SCHEMBL6829746 | 0.90 | FBP1 (0.81) | FBP1 | |
| SCHEMBL4955784 | 0.89 | FBP1 (0.86) | FBP1 | |
| SCHEMBL6829853 | 0.89 | FBP1 (1.00) | FBP1 | |
| SCHEMBL6829691 | 0.89 | FBP1 (0.80) | FBP1 | |
| SCHEMBL4957130 | 0.89 | FBP1 (1.00) | FBP1 | |
| SCHEMBL6829770 | 0.89 | FBP1 (1.00) | FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1060182-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | Metabasis Therapeutics, Inc. (US) | 2000-12-20 | — | — | EP | claimed |
| WO-1999045016-A9 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999045016-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS, INC. (US) | 1999-09-10 | — | — | WO | claimed |
| EP-1060182-B1 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| US-7563774-B2 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563774-B2 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7351399-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | METABASIS THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| EP-0970095-B1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
| US-6399782-B1 | ANTIDIABETIC AGENTS | METABASIS THERAPEUTICS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6110903-A | INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE AT THE AMP SITE; ADMINISTERING TO TREAT DIABETES AND INHIBIT GLUCONEOGENESIS; 5-FLUORO-7-BROMO-1-ISOBUTYL-2-(2-PHOSPHONO-5-FURANYL) BENZIMIDAZOLE, FOR EXAMPLE | SANKYO COMPANY LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0970095-A1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998039343-A9 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | — | 1999-01-21 | — | — | WO | disclosed |
| WO-1998039343-A1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | FBP1 1/4885 |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | FBP1 1/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | FBP1 1/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | FBP1 1659/4885 |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | FBP1, G6PC1, IRS1 | FBP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.